Highlights Type 1 diabetes is an incurable disease; achieving glycemic control remains very challenging across all the age groups. It has been observed that a hybrid closed-loop system improves glucose control and reduces the risk of developing hypoglycemia in comparison to the sensor-augmented pump therapy among individuals with suboptimally controlled Type 1 diabetes. This Journal Watch discusses the clinical trial from The Lancet, “Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicenter, 12-week randomized trial” . Authors : Tauschmann. M.; et.
al. What was the need for the study? Maintenance of glycemic control is very challenging in Type 1 diabetes individuals and chances of developing hypoglycemia is often higher due to the tight glycemic control. Over the past few years, various developments have been made in terms of closed-loop insulin delivery…
